Press

2021-05-24

Kancera announces that an application for a clinical phase IIa study with KAND567 after heart attack has been submitted to the UK Medicines Agency (MHRA)

Kancera AB (Nasdaq First North Premier Growth Market: KAN) announces today that the application for permission to start a phase IIa study evaluating the safety and cardioprotective effect of KAND567 in heart attack patients has been submitted to the...

Read More
2021-05-21

Interim report for first quarter 2021, 1 January – 31 March 2021

First quarter in brief Net sales for the period (January to March) amounted to SEK 0 million (SEK 0 million). R&D costs for the period amounted to SEK 8,2 million (SEK 9,7 million). Operating profit for the period amounted...

Read More
2021-01-15

Kancera provides update on successful phase I study and planned phase II study with KAND567 treatment following heart attack

This is a translation of a press release in Swedish published December 29, 2020

Read More
2021-01-15

Kancera appoints a Scientific Advisory Board with leading scientists in cardiology and immunology

This is a translation of a press release in Swedish published December 21, 2020

Read More
2020-12-02

Agreement on development of HDAC6 inhibitors discontinued.

Kancera AB announces today that the pharmaceutical company Grünenthal GmbH has chosen to terminate the parties' research and option agreement. Since the end of 2018, Grünenthal has been responsible for the development of Kancera's series of HDAC6 inhibitors and...

Read More